Trop2-imaging dye helps find early bladder cancer during surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses a special imaging dye that targets a protein called Trop2, which is often found on bladder cancer cells. During your surgery, the dye will help doctors see the cancer more clearly with advanced imaging so they can remove it completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have suspected early-stage bladder cancer that hasn't invaded muscle, and you are planning to have surgery
- Your overall health is good enough for surgery (no serious heart, lung, or bleeding problems)
- You are able to understand the study and give your informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new imaging agent (99mTc-MY6349) to see if it can detect Trop2, a protein found on some breast cancer cells. It may help doctors better see and understand triple-negative breast cancer that has spread.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This trial tests a new optical probe that gives doctors a clearer view of bladder tumors during cystoscopy. It may help make diagnosis and treatment more accurate.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.